Drugs Made In America Acquisition Corp. (DMAA) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Drugs Made In America Acquisition Corp., updated every trading day.
Other
Price
$10.87
0.00% today
Market cap
—
Overall quality
53/100
Kronos AI 30-day
−1.5%
0 of 8 simulated paths end higher
Drugs Made In America Acquisition Corp. (DMAA) is a US-listed company. It trades at $10.87, up 0.00% today, at 44 times earnings. Its overall quality score is 53 out of 100, ranked against the whole US market. Kronos AI's 30-day forecast is −1.5% (0 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
No analyst covers this listing yet.
Kronos AI 30-day forecast
| Expected close | $10.71 (−1.5%) |
| Likely range | −1.9% … −1.2% |
| As of | 2026-10-27 |
0 of 8 simulated paths end higher.
Quality scores
| Profitability | 50 |
| Solvency | 65 |
| Growth | 44 |
| Overall | 53 |
| P/E | 44 |
Shariah screen
| Business activity | Not decided |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
For information only, not investment advice. Prices updated: 2026-10-29.